Abstract. This study aimed to clarify the molecular mechanisms involved in ovarian carcinogenesis, and to identify candidate molecular targets for its diagnosis and treatment. The genome-wide gene expression profiles of 22 epithelial ovarian carcinomas were analyzed with a microarray representing 38,500 genes, in combination with laser microbeam microdissection. A total of 273 commonly up-regulated transcripts and 387 down-regulated transcripts were identified in the ovarian carcinoma samples. Of the 273 up-regulated transcripts, only 87 (31.9%) were previously reported as upregulated in microarray studies using bulk cancer tissues and normal ovarian tissues for analysis. CHMP4C (chromatinmodifying protein 4C) was frequently overexpressed in ovarian carcinoma tissue, but not expressed in the normal human tissues used as a control. Our data should contribute to an improved understanding of tumorigenesis in ovarian cancer, and aid in the development of diagnostic tumor markers and molecular-targeting therapy for patients with the disease.
Introduction
Ovarian cancer is the second most common gynecologic malignancy and the fifth leading cause of cancer-related death in women. As there are no specific indicators or symptoms of ovarian cancer during the early stages of the disease, the majority of patients with epithelial ovarian cancer (EOC) are diagnosed at an advanced stage, with involvement of other sites such as the upper abdomen, pleural space and paraaortic lymph nodes. The cancer antigen 125 assay (CA-125) has been used to screen for ovarian cancer, but is not specific; only 50% of patients with early ovarian cancer test positive using this assay (1) . The prognosis for ovarian cancer patients remains poor and largely dependant on the stage at diagnosis, with a 5-year survival rate of 45% (2) . Chemotherapy is the most common choice of treatment for patients at advanced stages, but often causes severe adverse reactions without affecting the tumor. Hence, the identification of new markers for early diagnostics and molecular targets that can be applied to the development of new treatment is eagerly anticipated.
Genome-wide microarray analysis enabled us to obtain comprehensive gene expression profiles related to the phenotypic and biological information of cancer cells (3, 4) . We identified multiple targets that may prove useful in the development of novel anti-cancer drugs and/or diagnostic biomarkers. In ovarian carcinoma, this approach can also be applied to identify unknown molecules involved in the carcinogenic pathway.
Through the gene expression profile analysis of 22 epithelial ovarian cancers coupled with purification of the cancer cell population by laser microbeam microdissection (LMM) on a microarray consisting of approximately 38,500 transcripts, we identified a number of transcripts that were overexpressed in ovarian cancers. We report important information regarding the mechanisms of ovarian carcinogenesis, as well as the discovery of potential targets for the development of diagnostic markers and novel therapeutic strategies for ovarian cancer.
Materials and methods
Tissue samples and microdissection. Twenty-two ovarian cancer tissue samples (median patient age 54 years, range
Genome-wide gene expression profiles of ovarian carcinoma:
Identification of molecular targets for the treatment of ovarian carcinoma 27 -75 years; Table I ) were obtained with written informed consent. The samples were collected from patients who underwent surgical procedures at the University Hospital of Obstetrics and Gynecology (Sofia, Bulgaria) and the General Hospital of Oncology (Sofia, Bulgaria). Cancer tissues were examined by professional pathologists at the hospitals. All 22 samples were determined to be epithelial ovarian carcinomas; one sample was classified as clear cell, two as mucinous carcinomas and the remaining 19 cases as serous types. Clinical information was obtained from medical records. Clinical stage was judged according to the UICC TNM classification. All specimens were embedded in TissueTek OCT medium (Sakura, Tokyo, Japan) immediately after surgical resection and stored at -80˚C until use. These frozen tissues were cut into 8-μm sections using a cryostat (Sakura, Tokyo, Japan) and then stained with hematoxylin and eosin (H&E) for histological examination. Ovarian cancer cells and corresponding normal ovarian epithelial cells were selectively collected using the EZ cut system with a pulsed ultraviolet narrow beam-focus laser (SL Microtest GmbH, Jena, Germany) according to the manufacturer's protocols. The layer of normal epithelial cells was collected from eight samples by LMM, and the mixture of RNA extracted from them served as a 'universal control' for hybridization.
Affymetrix GeneChip hybridization. The affymetrix human genome U133 Plus 2.0 GeneChip array was employed for microarray hybridization. This GeneChip comprises more than 54,000 probe sets and analyzes the expression level of 38,500 genes. For microarray hybridization, we followed the protocol described in the Affymetrix GeneChip eukaryotic two cycle target preparation protocol (Affymetrix). For the first-round synthesis of double-stranded cDNA, 100 ng of total RNA was reversely transcribed using the Two-Cycle cDNA Synthesis Kit (Affymetrix, Santa Clara, CA) and T7-oligo-dT primer according to the manufacturer's instructions, followed by IVT amplification with the MEGAscript T7 Kit (Ambion Inc., Austin, TX). After cleanup of the cRNA with a GeneChip Sample Cleanup Module IVT column (Affymetrix), second-round double-stranded cDNA was amplified using the IVT Labeling Kit (Affymetrix). A 20 μg aliquot of the labeled product was fragmented by heat and ion-mediated hydrolysis at 94˚C for 35 min in H 2 O combined with 8 μl of 5x Fragmentation Buffer (Affymetrix). The fragmented cRNA was hybridized for 16 h at 45˚C in a Hybridization Oven 640 to a U133 Plus 2.0 oligonucleotide array (Affymetrix). Washing and staining of the arrays with phycoerythrin-conjugated streptavidin (Molecular Probes, Eugene, OR) was completed in a Fluidics Station 450 (Affymetrix). The arrays were then scanned using a confocal laser GeneChip Scanner 3000 (Affymetrix).
Data analysis. Global normalization at a target value of 500 was applied to all 23 arrays (22 cancer arrays and one array of the universal control) under consideration using GeneChip Operating Software (Affymetrix). Normalized data from text files were imported to a Microsoft Excel spreadsheet. Because data derived from low signal intensities are less reliable, we Table I . Clinicopathological features of ovarian cancer clinical samples used for microarray analysis.
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excluded transcripts with low intensities from further analysis when the signal intensities of both normal and cancer cells were lower than that of the cut-off value. For the other genes, we calculated the signal intensities of the cancer/normal ratio using the raw data of each sample. Up-regulated or downregulated genes were selected based on the signal intensity of their cancer/normal ratio (r): up-regulated, r>5.0; and downregulated, r<0.2.
Calculation of contamination proportion. GSG2 (germ cellspecific gene 2), a gene that is expressed exclusively in ovarian germ cells, was used to evaluate the proportion of germ cells present in the population of microdissected normal surface epithelial cells. Each intensity was normalized to the intensity of the ß-actin gene (ACTB) as follows: Ratio A, the GSG2/ ACTB intensity ratio in the whole normal ovarian tissue (where some of the cells correspond to germ cells); the signal intensity of poly (A) + RNA isolated from whole normal ovarian tissue was 0.2939. Ratio B, the GSG2/ACTB intensity ratio in microdissected normal ovarian epithelial cells = 0.0036 (a mixture of normal ovarian epithelial cells from eight individuals as a universal control). The proportion of the contamination was calculated as [(Ratio B)/(Ratio A)] x 100 = 1.24%.
Semi-quantitative RT-PCR.
RNA from the purified populations of ovarian cancer cells and from normal epithelial cells was extracted using the RNeasy Micro Kit (Qiagen, Valencia, CA) and treated with DNase I according to the manufacturer's recommendations. Extracted RNA was subjected to two rounds of RNA amplification using T7-based in vitro transcription (Invitrogen), and amplified RNA were reverse-transcribed to single-stranded cDNA using random primer with Superscript II reverse transcriptase (Invitrogen). We prepared appropriate dilution of each single-stranded cDNA for subsequent PCR amplification, and monitored their reactions using ACTB as a quantitative control, as it showed the smallest fluctuations in the cancer/normal ratio in our ovarian cancer microarray data. PCR amplification was performed using single-stranded cDNA as a template and gene-specific primers (Table II) . PCR reactions were optimized for the number of cycles to ensure product intensity within the logarithmic phase of amplification.
Northern blot analysis. Human multiple tissue Northern (MTN) blots (BD Biosciences, Palo Alto, CA) were hybridized for 16 h with 32 P-labeled PCR product of CHMP4C (chromatin modifying protein 4C) cDNA. The cDNA probe of CHMP4C was prepared by RT-PCR using the primers 5'-CAATGAG CAAGTTGGGCAAG-3' and 5'-CCAAGCTGCCAATTG TTTG-3'. Prehybridization, hybridization and washing were performed according to manufacturer's recommendations. The blots were autoradiographed with intensifying screens at -80˚C for 14 days.
Results

Identification of commonly up-regulated or down-regulated genes in ovarian carcinoma.
To obtain the precise gene expression profiles of ovarian cancer cells, we employed LMM to purify both epithelial cancerous cells and normal epithelial cells (Fig. 1A-I) . We estimated the proportion of germ cells in the microdissected population of normal ovarian epithelial cells by measuring the signal intensities of GSG2 (germ cell-specific gene 2), which is highly and specifically expressed in human haploid germ cells (5) (6) (7) (8) . When the signal intensity of this gene was compared in whole normal ovarian tissue and microdissected normal ovarian epithelial cells, the average ratio of signal intensity was calculated to be ~98.77%, indicating that the proportion of germ cells in the microdissected normal ovarian epithelial cells was ~1.24% (described in Calculation of contamination proportion, Materials and methods) (9) .
We searched for genes commonly up-and down-regulated in ovarian cancer according to the following criteria: i) genes for which expression data, defined as described in Materials and methods, was obtained in ≥50% (11/22) of the cases examined; and ii) genes whose expression ratio was >5.0 or <0.2 in ≥50% of the informative cases. According to these criteria, a total of 273 transcripts were selected as commonly up-regulated genes (Table III) , and 387 as commonly downregulated genes (Table IV) 
) and immune response (CD24, ITGB6, CD164). Among the up-regulated genes identified, WAPDC2 and SPP1 were previously reported to be genes activated in serous epithelial ovarian cancer compared with bulk normal ovarian tissue (10) . TOP2A, MUC1 and SFN, which have already been proven to be implicated in chemoresistance and tumorigenesis, are also included in the up-regulated genes (11) . The FGF and WNT signaling pathways are represented by different members among the up-regulated genes. Although they were shown to have direct or indirect effects on ovarian carcinogenesis, their functional significance remains to be clarified. Some of the up-regulated genes have been found to be overexpressed not only in ovarian carcinoma, but also in a number of other malignancies. Elevated mRNA expression of RHAMM (hyaluronan-mediated motility receptor) was also found in patients with CML (40%), renal cell carcinoma (73%), breast carcinoma (60%) and ovarian carcinoma (50%) (12, 13) . BCL11A (b-cell cll/lymphoma 11a) is involved in both lymphoid malignancies and, with a significant amplification, in ovarian cancer (14) .
Furthermore, 387 genes were identified whose expression levels were reduced to ≤20% in ovarian cancer compared with normal epithelial cells (Table IV) . Certain of these were to some extent previously functionally characterized. Such genes have been implicated in the regulation of transcription (ZFPM2, NR2F1, HOXC6, TCF4) , the regulation of cell growth and the cell cycle (IGFBP5, HTRA1, GAS1, MCC, NBL1, NDN), transport molecules (COL6A3, COL3A1, SYTL4, FXYD6, DPYD, COL16A1) and signal transduction (ANK2, CAV1, RAB31, BNC2). They include genes that are, it has been suggested, related to chemosensitivity (TRA1) and cell cycle control (SMOC2, TIMP3). The reduced expression of the genes in tumor cells may imply that they play a role in the suppression of cell growth or the inhibition of invasion. For example, PEG3 (paternally expressed gene 3), which activates NF-κB, was suggested to have a tumor suppressive function (15) . SPARC, an extracellular Ca(2+)-binding matricellular glycoprotein, was reported to be a potent antiproliferator with proapoptotic functions (16) . HTRA1 and CAV1 also have potential antiangiogenic and antiproliferative roles, and are included in the down-regulated genes (17) (18) (19) (20) .
Identification of CHMP4C as a molecular target gene for ovarian cancer therapy. To validate the expression data obtained using microarray analysis, we performed semiquantitative RT-PCR for a total of 20 representative genes found to be frequently overexpressed in ovarian cancer cases, using samples from 17 clinical ovarian cancer cases. These genes were confirmed as highly expressed in all or most of the ovarian cancer cases examined, while their expression could not be detected in normal ovarian surface epithelial cells (seven genes are shown in Fig. 2A) . The results of RT-PCR using ovarian cancer materials were very concordant with those of the microarray analysis. Table III . Genes commonly up-regulated in ovarian cancer. Table III . Continued. Table III . Continued. --------------------------------------------------------------------------------------------------- -Table IV . Genes commonly down-regulated in ovarian cancer. Table IV . Continued. ----------------------------------------------------------------------------------------------------- Among the genes up-regulated in ovarian cancer ( Fig. 2A) , we focused on CHMP4C (chromatin modifying protein 4C) for further biological analysis as it was commonly overexpressed in clinical ovarian cancer samples but not expressed in any of the normal human tissues examined. Subsequent Northern blot analysis using a CHMP4C cDNA fragment as a probe confirmed that an ~1.9 kb transcript was hardly detectable in normal human tissues, with the exception of the prostate and a very weak band in the small intestine (Fig. 2B) .
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Discussion
Recent progress in genomic and molecular analysis has improved our understanding of the genesis of a wide range of human neoplasms. For ovarian carcinoma, several groups have reported the results of microarray-based expression profile analysis and identified so-called candidate genes that may be applicable as diagnostic markers (21) (22) (23) (24) (25) (26) . However, tumor tissue is generally a mixture of various cell types, such as inflammatory cells, stromal cells, endothelial cells and fibroblasts, in addition to cancer cells, and the proportions of each cell type vary significantly from one individual to another. Hence, expression profile data using mRNA isolated from bulk tumor tissue are very unlikely to exactly reflect changes during the course of ovarian carcinogenesis. In addition, normal ovarian tissue is also a mixture of different cell types. Since epithelial ovarian carcinomas (EOCs) are considered to originate from ovarian epithelial cells on the surface of the ovaries, it is preferable to use normal ovarian epithelial cells as a control to determine differences in expression levels related to the process of ovarian carcinogenesis. Therefore, in this study, we performed laser microbeam microdissection (LMM) to enrich populations of ovarian cancer cells as well as control ovarian surface epithelial cells. Upon comparison of our data and the data of a previous expression profile of ovarian cancer using RNA from bulk tumor tissues (24) , only 87 of the 273 transcripts that we identified to be commonly up-regulated in over 50% of informative ovarian cancer cases, shown in Table III , overlapped with the bulk expression profile data. We assume that this discrepancy is attributable to the difference in the sample preparation process used, and that our data more precisely demonstrate the expression changes during the carcinogenesis process from ovarian epithelial to malignant cells. To evaluate the purity of microdissected cell populations, we analyzed the expression of GSG2 (germ cell specific gene 2), which is abundantly expressed in germ cells in our gene expression profiling. By careful application of the microdissection procedure, we were able to minimize the proportion of contaminating germ cells to as few as 1.24% in preparations of normal ovarian epithelial cells. Indeed, upon comparison of our data with the previous expression profile data of ovarian cancer obtained by means of microarray (21) (22) (23) (24) (25) (26) , only 46 of the 387 transcripts identified as commonly down-regulated in over 50% of informative ovarian cancer cases (Table IV) overlapped with the bulk expression profile data. Therefore, 341 genes that had not previously been identified as down-regulated were identified as downregulated genes in this study. Among these 341 downregulated genes, we found GAS1 (growth arrest-specific 1), ZFPM2 (zinc finger protein, multitype 2) and NBL1 (neuroblastoma, suppression of tumorigenicity 1), which are reported to be a negative regulator of epithelial cell proliferation, a DNA-dependent regulator of transcription and a transcription factor with tumor-suppressive activity, respectively (27) (28) (29) (30) . This suggests that the majority of down-regulated genes, including genes with a tumor-suppressive function, were not detected in previous studies. We believe that it is crucial to apply the LMM system to purify populations of cancerous and normal epithelial cells obtained from surgical specimens to the greatest extent possible, in order to improve our understanding of the genes involved in carcinogenesis.
Certain of the genes with altered expression in most ovarian cancers may play causal roles in ovarian carcinogenesis, and may also serve as molecular diagnostic markers and candidate targets for the development of novel therapeutic drugs for ovarian cancer. Among the up-regulated genes, CD24 (CD24 antigen), EVI1 (ecotropic viral integration site 1), MDS1 (myelodysplastic syndrome 1), HOXB7 (homeobox B7), GPR39 (G protein-coupled receptor 39) and CP (ceruloplasmin) were previously reported to be up-regulated in ovarian cancer (21) (22) (23) (24) (25) (26) . Many studies have demonstrated the significance of the cytoplasmic membranous expression of CD24 in the prediction of the prognosis of ovarian cancer patients (31) (32) (33) (34) (35) . Protein levels of EVI1 and MDS1 were reported to be increased in both ovarian cancer tissues and ovarian cancer cell lines (36) . Nanjundan et al (36) recently revealed that DNA copy number increases of both genes were associated with at least 5-fold-increased RNA transcript levels in 83 and 98% of advanced ovarian cancer cases, respectively. The high expression level of homeobox member gene HOXB7 mRNA reveals its possible involvement in the invasive characteristics of ovarian cancer cells (37, 38) . GPR39 was found to be a novel inhibitor of cell death, which might represent a therapeutic target with implications for processes involving apoptosis and endoplasmic reticulum stress in cancer (39) . CP is associated with an unfavorable prognosis and poor outcome in patients with ovarian cancer (40) . Its mRNA expression levels were found to be elevated in 17 of the 22 clinical tumor cases in the present study (77.3%).
In addition to genes that have been characterized broadly or partially in tumor cell growth and development, we found several novel genes, which deserve to be investigated as molecular markers for diagnostics and treatment of ovarian cancer. CASZ1 (castor zinc finger 1) was recently cloned and found to be up-regulated during cell differentiation, and was expressed in a number of human tumors (41) . STAM2 (signal transducing adaptor molecule 2) is a regulator of receptor signaling and trafficking (42) . KIF2C (kinesin family member 2c) has so far been connected with mammary carcinogenesis (43) and was found to be overexpressed in human gastric cancer (44) . Its role in ovarian carcinogenesis remains to be investigated. RAB3IP (rabin), F11R (F11 receptor), TMEM45B (transmembrane protein 45B), FAM108C1 (family with sequence similarity 108, member C1), C1orf106 (chromosome 1 open reading frame 106), MPZL2 (myelin protein zero-like 2), TRIP13 (thyroid hormone receptor interactor 13), IRF6 (interferon regulatory factor 6), FAM83H (family with sequence similarity 83, member H), MYO5C (myosin 5C) are some of the novel genes identified in the present study that are significantly overexpressed in the majority of clinical cases. RIPK4 (receptor-interacting serine-threonine kinase 4) and CHMP4C (chromatin modifying protein 4C) were very highly expressed in the majority of the clinical samples according to RT-PCR, and were not detected in the normal ovarian tissues. RIPK4 is an ankyrin-repeat containing protease, while CHMP4C belongs to the chromatin-modifying protein/charged multivesicular body protein (CHMP) family. Neither have been analyzed in relation to cancer, and both warrant future investigation as potential therapeutic targets for ovarian cancer therapy.
Among the 387 commonly down-regulated genes, PEG3 (paternally expressed 3), HTRA1 (HtrA serine peptidase 1), CAV1 (caveolin 1), Dab2 (disabled homolog 2), SPARC (secreted protein, acidic, cysteine-rich) were detected. Certain of these were previously suggested to have possible functions as tumor suppressors. PEG3 was shown to be silenced by hypermethylation in endometrial and cervical cancer cell lines (15) . HTRA1 was reported to be down-regulated in ovarian tumors and cancer cell lines, suggesting that its loss plays a role in the progression of cancer (45) . A microarray study of advanced stage ovarian carcinomas revealed down-regulation of the CAV1 (caveolin-1) gene in ovarian carcinomas. Immunohistochemical analysis confirmed loss of CAV1 expression in serous ovarian carcinomas (18) . By studying Dab2 in 50 primary ovarian tumors and in 50 metastases by immunohistochemistry, it was shown that Dab2 was absent in the majority of ovarian tumors at both primary and metastatic sites (46) . Certain of the down-regulated genes are supposed to be silenced by hypermethylation in tumors and implemented in the process of tumor cell growth. Down-regulation of SPARC is thought to be essential for ovarian carcinogenesis, as cancer cells become sensitized to the apoptotic activity of SPARC during malignant transformation (24, 47) . TGFBR3 (transforming growth factor ß, receptor III) and THBS2 (thrombospodin 2) have also been found to be highly expressed in normal ovarian epithelia and underexpressed in ovarian serous papillary carcinomas (24) .
Novel down-regulated genes in the present study included CLEC2B (C-type lectin domain family 2, member B) and MCC (mutated in colorectal cancers). CLEC2B is preferentially expressed in lymphoid tissues, and its transcription is transiently up-regulated during lymphocyte activation by PMA (paramethoxyamphetamine). MCC is a known tumor suppressor gene in colorectal cancers (48) , but its role in ovarian cancer remains unknown. EFEMP1 (egf-containing fibulin-like extracellular matrix protein 1) is related with retinal dystrophy, and is also inactivated in lung cancer by promoter hypermethylation (49, 50) . Its role in reducing tumor angiogenesis (51) could possibly explain how the development of ovarian tumors is connected with a reduced expression of this gene. RBMS3 (rna-binding motif protein, single strandinteracting, 3) is a non-transcriptional regulator that binds to ssDNA and A/U rich stretches of RNA. It is activated in liver fibrosis and can connect the transcriptional factor Prx1 (52) .
Among the up-regulated genes, we identified CHMP4C as a possible molecular target for ovarian cancer therapy due to its frequent transactivation in ovarian cancers and its undetectable levels of expression in any human adult normal tissues. CHMP4C belongs to the CHMP family, a family of small coiled-coil proteins involved in multivesicular body sorting through its participation in ESCRT-III (endosomal sorting complex required for transport III). CHMP4C contains an Snf7 domain which is a conserved 132-amino acid sequence among all of the 10 family members (CHMP1A, 1B, 2A, 2B, 3, 4A, 4B, 4C, 5, and 6) (53). Following its cloning in 2004, the interaction of CHMP4C with Alix was reported after co-immunoprecipitation experiments were performed using lysates of HEK293 cells (54) . A more recent article indicates interaction between CHMP4C and CC2D1A (53) . So far, the gene has not been mentioned in relation to ovarian carcinogenesis. Its role as a potential therapeutic target remains to be evaluated.
We demonstrated that the use of microarray represents a powerful approach to identifying key molecules in the development and progression of ovarian cancer. Additionally, we identified several genes whose elevated or decreased expression has not been previously observed in ovarian cancer, confirmed the validity of several existing markers, and provided a foundation for future studies in the understanding and management of this disease. A number of candidates reported here should provide new markers that may contribute to the precise and timely diagnosis of ovarian cancer. Observed changes in the expression profiles of tumor and normal ovarian tissue are due to the combined action of different classes of genes implicated in the mechanisms of transcription, tumor invasion/progression and the regulation of cell the cycle and growth. In summary, gene expression profiling has demonstrated the specific expression signatures of epithelial ovarian tumors as compared to their normal counterparts. An extended study of some of the identified ovarian candidate genes will ensure an improved understanding of the mechanisms of ovarian carcinogenesis and the existence of different subtypes of ovarian cancer.
